Phillip Koo, MD, has been appointed chief medical officer of Santa Monica, Calif.-based Prostate Cancer Foundation. Dr. Koo ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

The reception was part of a weekend of events which included a seminar at Palm Beach Atlantic University and a luncheon at ...

Noetik Names Dr. Emily Corse Executive Vice President of Therapeutics to Accelerate AI-Powered Therapeutics Pipeline ...

The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, ...

The University of Texas MD Anderson Cancer Center has commenced construction on a new 470,000ft² facility in Sugar Land, aiming to enhance cancer care services in Southwest Houston. Scheduled to ...

Houston-based University of Texas MD Anderson Cancer Center broke ground on a new facility in Sugar Land, Texas, set to be ...

Oncologists share how to prioritize yourself while undergoing the difficult treatment, and real women share how positive ...

The University of Texas at Austin and MD Anderson Cancer Center plan to build two new hospital towers in the downtown ...

James Ragan died more than a decade ago, but his impact on the life of Scottie Scheffler hasn't diminished since they first ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

The University of Texas MD Anderson Cancer Center today announced that Jeffrey E. Lee, M.D., an internationally regarded leader in the field of oncology, has been appointed chief medical executive ...